## moleculardimensions.com

## Morpheus $^{\text {TM }}$ MD1-46/ MD1-47

A 96 condition 3D protein crystallization screen with original chemistry incorporating a range of low molecular weight ligands found ordered in $\sim 33,000$ deposited structures. This unique screen aims to unlock novel chemical space previously inaccessible using conventional screens. Improved to accommodate easy optimisation of conditions*.

MD1-46 is presented as $96 \times 10 \mathrm{ml}$ conditions.
MD1-47 is presented as an HT screen with $96 \times 1 \mathrm{ml}$ conditions in deep-well blocks.

## Features of Morpheus ${ }^{\text {TM }}$ :

- Simple and effective 3D grid design covering a range of pH , PEGs and salt additives
- Targeted incorporation of 49 low molecular weight ligands observed to promote both initial crystal formation and lattice stability.
- Reduced crystal "stress" - all conditions are cryo-protected.
- Available in both 10 ml tube and HT-96 deep well block formats.
- Improved with NEW buffer systems to make optimisation simple.


## Introduction

Morpheus is a 96 condition protein crystallization screen with an original chemistry. It is based on extensive data mining of the PDB. The aim is to explore different chemical space than is achieved with conventional screening.
Morpheus incorporates 49 low molecular weight components. They are PDB ligands sharing four main characteristics; they are small (the largest being HEPES MW $238.30 \mathrm{~g} / \mathrm{mol}$ and the smallest a lithium ion MW $6.94 \mathrm{~g} / \mathrm{mol}$ ), stable, inexpensive and are associated with at least five unrelated PDB structures.

The selection of ligands are listed in Table 1 (data produced on the $14^{\text {th }}$ of July 2008: 35759 structures with ligands in the PDB). Overall the PDB ligands in Morpheus correspond with over 33,000 PDB structures. For instance, the two enantiomers of tartaric acid (PDB ID: TAR and TLA) are found ordered in 113 structures.

Preliminary tests with Morpheus made within the Laboratory of Molecular Biology (LMB) ${ }^{1}$ at Cambridge, UK,
have shown encouraging results with various targets. In some cases, Morpheus gave hits when all other commercial screens had failed.
Figure 1 shows examples of protein crystallization hits observed while testing Morpheus.

## Screen Design

Morpheus is based on a 3D grid design (Figure 2). Thirty of the top PDB ligands from Table 1 are grouped into eight mixes of additives depending on their chemical class (e.g. alcohols, carboxylic acids, etc) (Table 2).
These top PDB ligands also happen to be "biological buffers" like HEPES (PDB ID: EPE, 201 hits) and have been used to build three buffer systems*. Each buffer system includes different buffers with close pKa's (Table 3).
There are nine precipitants included in the composition of Morpheus. They are grouped into four mixes of precipitants (Table 4). The main characteristic of the four mixes is that they contain at least a PEG (Polyethylene glycol) and a different type of precipitant that is also a cryo-agent (e.g. Glycerol). All the conditions of Morpheus are cryo-protected to minimize further mechanical stress on the crystals.

Each mix of precipitants is systematically tested with all the mixes of additives and the mixes of buffers. The proportions of stocks are always the same for making any condition of the three-dimensional grid: 5:1:1:3 of precipitants, ligands, buffers and water respectively. When almost a third of the composition is water, there is space for making an optimization screen with higher concentration of any mix/component.


Figure 1. Examples of successful crystallization with Morpheus


Figure 2. Schematic of Morpheus ${ }^{T M}$ - A three-dimensional grid screen
*Optimisation is now easily achieved because of the improvements made to the buffer systems used in Morpheus. The user now has complete control over what pH they would like to optimise at. The original Buffer Mixes will still be available to purchase from Molecular Dimensions Ltd.

## Formulation notes

The reagents in Morpheus are formulated using ultrapure water ( $>18.0 \mathrm{M} \Omega$ ) and are sterile-filtered using $0.22 \mu \mathrm{~m}$ filters. No preservatives are added.
Final pH may vary from that specified on the datasheet.

## Contact Us

Individual reagents and stock solutions for optimization are available from Molecular Dimensions.

Molecular Dimensions Ltd. would be very grateful if investigators were prepared to provide feedback on their own experiences with the new screen. Crystallization reports or pictures can be e-mailed to: enquiries@moleculardimensions.com

Contact and product details can be found at www.moleculardimensions.com

## References

1. D. Stock, O. Perisic, J. Löwe "Robotic nanolitre protein crystallisation at the LMB", Prog. Biophys. Mol. Biol. 88 (2005) 311-32See also LMB-Cambridge robotic crystallisation web pages: http://www2.mrc-Imb.cam.ac.uk/groups/JYL/WWWrobots/

This product has been designed and developed by Fabrice GORREC, in collaboration with the scientists at the Medical Research Council Laboratory of Molecular Biology (LMB) at Cambridge and is manufactured exclusively under license by Molecular Dimensions Limited.

Limited Use and Restrictions: Products sold by Molecular Dimensions Ltd. or its affiliates or authorized distributors and information relating to same are intended for research use only in crystal growth and optimization of crystal growth following use of the product by the purchaser and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, including resale or use in manufacture. The license to use Morpheus ${ }^{\text {TM }}$ specifically excludes any rights to use the product information for the manufacture of the product or derivatives thereof, or distribute, transfer, or otherwise provide access to such information to any third party for any purpose or use.

## moleculardimensions.com

Table 1: List of PDB ligands in Morpheus

| PDB Ligand name(s) | Class | PDB I D(s) | Structure Hits* |
| :---: | :---: | :---: | :---: |
| 1,2-Ethanediol (ethylene glycol) | Precipitant | EDO, EGL | 1081 |
| 1,2-Propanediol (enantiomers R and S) | Alcohols | PGO, PGR | 41 |
| 1,3-Propanediol | Alcohols | PDO | 7 |
| 1,4-Butanediol | Alcohols | BU1 | 11 |
| 1,6-Hexanediol | Alcohols | HEZ | 19 |
| 1-Butanol | Alcohols | 18O | 7 |
| 2-(N-Morpholino)-ethane sulfonic acid (MES) | Buffer | MES | 315 |
| 2-Amino-2-hydroxymethyl-propane-1,3-diol (Tris) | Buffer | TRS | 334 |
| 2-Methyl-2,4-pentanediol (MPD, enantiomers R and S) | Precipitant | MPD, MRD | 504 |
| 3-Morpholinopropane-1-sulfonic acid (MOPS) | Buffer | MPO | 21 |
| 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) | Buffer | EPE | 201 |
| Acetic acid, acetate, acetyl | Carboxylic acids | ACY, ACT, ACE | 1890 |
| ( $S$-2-Aminopropanoic acid (Alanine, (enantiomers L and D) | Amino acids | ALA, DAL | 35 |
| Amino, Ammonia, Ammonium | multiple | NH2, NH3, NH4 | 582 |
| $\mathrm{N}, \mathrm{N}$-bis(2-hydroxyethyl)glycine (Bicine) | Buffer | BCN | 13 |
| Bromide | Halogens | BR | 120 |
| Calcium | Divalents | CA | 3959 |
| Chloride | Multiple | CL | 2842 |
| Citric acid, citrate | Carboxylic acids | CIT, FLC | 384 |
| D-Galactose (anomers a and $\beta$ ) | Monosaccharides | GAL, GLA | 86 |
| D-Glucose (anomers a and $\beta$ ) | Monosaccharides | GLC, BGC | 206 |
| Di(Hydroxyethyl)ether (Di-Ethyleneglycol) | Ethylene glycols | PEG | 209 |
| D-Mannose (anomers a and $\beta$ ) | Monosaccharides | MAN, BMA | 178 |
| D-Xylopyranose (anomers a and $\beta$ ) | Monosaccharides | XYL, XYP | 41 |
| Fluoride | Halogens | F | 16 |
| Formic acid | Carboxylic acids | FMT | 267 |
| Glycerol | Amino acids | GOL | 2884 |
| Glycine | Buffer | GLY | 50 |
| Imidazole | Halogens | IMD | 154 |
| Iodide | Alcohols | IOD | 178 |
| Isopropyl alcohol (iso-propanol, 2-Propanol) | Monosaccharides | IPA, IOH | 174 |
| L-Fucose (anomers a and $\beta$ ) | Amino acids | FUC, FUL | 62 |
| L-Glutamic acid | Precipitant | GLU | 66 |
| Lysine (enantiomers L and D) | Amino acids | LYS, DLY | 36 |
| Magnesium | Divalents | MG | 3991 |
| N-Acetyl-d-glucosamine (anomers a and $\beta$ ) | Monosaccharides | NAG,NBG | 1150 |
| Nitrate | NPS | NO3 | 156 |
| Oxamic acid | Carboxylic acids | OXM | 17 |
| Penta(hydroxyethyl)ether (Penta-Ethyleneglycol) | Ethylene glycols | 1PE | 91 |
| Phosphates | NPS | PO4, PI, 2HP | 1687 |
| Potassium | Carboxylic acids | K | 720 |
| Serine (enantiomers L and D) | Amino acids | SER, DSN | 38 |
| Sodium | multiple | NA | 1926 |
| Sulfate | NPS | SO4 | 5793 |
| Tartaric acid (enantiomers R and S) | Carboxylic acids | TAR, TLA | 113 |
| Tetra(hydroxyethyl)ether (Tetra-Ethyleneglycol) | Ethylene glycols | PG4 | 194 |
| Tri(Hydroxyethyl)ether (Tri-Ethyleneglycol) | Ethylene glycols | PGE | 107 |
| * as of July 2008. |  | SUM | 32956 |

DNED
DOED DDOD

## moleculardimensions.com

Table 2: Mixes of additives used in Morpheus ${ }^{\text {TM }}$

| Mix name | Composition | Catalogue Number ( 100 \& 250 mL ) |
| :---: | :---: | :---: |
| Divalents | $\mathrm{MgCl}_{2} ; \mathrm{CaCl}_{2}$ | MD2-100(250)-70 |
| Halogens | NaF; NaBr; NaI | MD2-100(250)-71 |
| NPS ${ }^{\dagger}$ | $\mathrm{NaNO}_{3} ; \mathrm{Na}_{2} \mathrm{HPO}_{4} ;\left(\mathrm{NH}_{4}\right)_{2} \mathrm{SO}_{4}$ | MD2-100(250)-72 |
| Alcohols | 1,6-Hexanediol; 1-Butanol <br> 1,2-Propanediol (racemic); 2-Propanol; 1,4- <br> Butanediol; 1,3-Propanediol | MD2-100(250)-73 |
| Ethylene glycols | Di-Ethyleneglycol; Tri-Ethyleneglycol; TetraEthyleneglycol; Penta-Ethyleneglycol | MD2-100(250)-74 |
| Monosaccharides | D-Glucose; D-Mannose; D-Galactose; LFucose; D-Xylose; N-Acetyl-D-Glucosamine | MD2-100(250)-75 |
| Carboxylic acids | Na-Formate; $\mathrm{NH}_{4}$-Acetate; $\mathrm{Na}_{3}$-Citrate; NaKTartrate (racemic); Na-Oxamate | MD2-100(250)-76 |
| Amino acids | L-Na-Glutamate; Alanine (racemic); Glycine; Lysine HCl (racemic); Serine (racemic) | MD2-100(250)-77 |

${ }^{\dagger}$ NPS; Nitrate Phosphate Sulfate.
Table 3: Buffer systems ${ }^{*}$ used in Morpheus ${ }^{T M}$

| Mix name | Conc. | pH @ $20^{\circ} \mathrm{C}$ | Composition | Catalogue Number <br> $(100 \& 250 \mathrm{~mL})$ |
| :--- | :--- | :--- | :--- | :--- |
| Buffer System 1 | 1.0 M | 6.5 | Imidazole;; MES (acid); | MD2-100(250)-100 |
| Buffer System 2 | 1.0 M | 7.5 | Sodium HEPES; MOPS (acid) | MD2-100(250)-101 |
| Buffer System 3 | 1.0 M | 8.5 | Tris (base); Bicine | MD2-100(250)-102 |

*These buffers have been improved to aid optimisation. The buffers in each system are un-titrated and mixed together to give the appropriate pH. Each Buffer system is available as an individual kit for your convenience (a Buffer composition table for these systems are available from our Downloads Centre).

Table 4: Mixes of Precipitants used in Morpheus ${ }^{T M}$

| Mix name | Conc. | Composition | Catalogue Number <br> $(100$ \& 250mL) |
| :--- | :--- | :--- | :--- |
| P550MME_P20K | $60 \%$ | PEGMME 550; PEG 20K | MD2-100(250)-81 |
| EDO_P8K | $60 \%$ | Ethylene glycol; PEG 8K | MD2-100(250)-82 |
| GOL_P4K | $60 \%$ | Glycerol; PEG 4K | MD2-100(250)-83 |
| MPD_P1K_P3350 | $75 \%$ | MPD (racemic); PEG 1K; <br> PEG 3350 | MD2-100(250)-84 |

The additive and precipitant mixes are available to buy from Molecular Dimensions Ltd.
For individual components or customised mixes please contact us directly at enquiries@moleculardimensions.com
moleculardimensions.com

Table 5- MD1-46 (MD1-47 HT) Morpheus ${ }^{\text {TM }}$ Conditions 1-48 (A1-D12)

| Well | Tube | Ligand stock | Conc. | Buffer System | Conc. | pH @ (20 $\left.{ }^{\circ} \mathrm{C}\right)$ | precipitant stock | Conc. |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| A1 | 1-1 | Divalents | 0.06M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| A2 | 1-2 | Divalents | 0.06M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| A3 | 1-3 | Divalents | 0.06M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| A4 | 1-4 | Divalents | 0.06M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| A5 | 1-5 | Divalents | 0.06M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| A6 | 1-6 | Divalents | 0.06M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| A7 | 1-7 | Divalents | 0.06M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| A8 | 1-8 | Divalents | 0.06M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| A9 | 1-9 | Divalents | 0.06M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| A10 | 1-10 | Divalents | 0.06M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| A11 | 1-11 | Divalents | 0.06M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| A12 | 1-12 | Divalents | 0.06M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |
| B1 | 1-13 | Halogens | 0.09M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| B2 | 1-14 | Halogens | 0.09M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| B3 | 1-15 | Halogens | 0.09M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| B4 | 1-16 | Halogens | 0.09M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| B5 | 1-17 | Halogens | 0.09M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| B6 | 1-18 | Halogens | 0.09M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| B7 | 1-19 | Halogens | 0.09M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| B8 | 1-20 | Halogens | 0.09M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| B9 | 1-21 | Halogens | 0.09M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| B10 | 1-22 | Halogens | 0.09M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| B11 | 1-23 | Halogens | 0.09M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| B12 | 1-24 | Halogens | 0.09M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |
| C1 | 1-25 | NPS | 0.09M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| C2 | 1-26 | NPS | 0.09M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| C3 | 1-27 | NPS | 0.09M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| C4 | 1-28 | NPS | 0.09M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| C5 | 1-29 | NPS | 0.09M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| C6 | 1-30 | NPS | 0.09M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| C7 | 1-31 | NPS | 0.09M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| C8 | 1-32 | NPS | 0.09M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| C9 | 1-33 | NPS | 0.09M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| C10 | 1-34 | NPS | 0.09M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| C11 | 1-35 | NPS | 0.09M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| C12 | 1-36 | NPS | 0.09M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |
| D1 | 1-37 | Alcohols | 0.12M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| D2 | 1-38 | Alcohols | 0.12M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| D3 | 1-39 | Alcohols | 0.12M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| D4 | 1-40 | Alcohols | 0.12M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| D5 | 1-41 | Alcohols | 0.12M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| D6 | 1-42 | Alcohols | 0.12M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| D7 | 1-43 | Alcohols | 0.12M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| D8 | 1-44 | Alcohols | 0.12M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| D9 | 1-45 | Alcohols | 0.12M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| D10 | 1-46 | Alcohols | 0.12M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| D11 | 1-47 | Alcohols | 0.12M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| D12 | 1-48 | Alcohols | 0.12M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |

Table 5 contd. - MD1-46 (MD1-47 HT) Morpheus ${ }^{\text {TM }}$ Conditions 49-96 (E1-H12)

| Well | Tube | Ligand stock | Conc. | Buffer System | Conc. | pH@ (20$\left.{ }^{\circ} \mathrm{C}\right)$ | Precipitant stock | Conc. |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: | :---: |
| E1 | 2-1 | Ethylene Glycols | 0.12M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| E2 | 2-2 | Ethylene Glycols | 0.12M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| E3 | 2-3 | Ethylene Glycols | 0.12M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| E4 | 2-4 | Ethylene Glycols | 0.12M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| E5 | 2-5 | Ethylene Glycols | 0.12M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| E6 | 2-6 | Ethylene Glycols | 0.12M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| E7 | 2-7 | Ethylene Glycols | 0.12M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| E8 | 2-8 | Ethylene Glycols | 0.12M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| E9 | 2-9 | Ethylene Glycols | 0.12M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| E10 | 2-10 | Ethylene Glycols | 0.12M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| E11 | 2-11 | Ethylene Glycols | 0.12M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| E12 | 2-12 | Ethylene Glycols | 0.12M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |
| F1 | 2-13 | Monosaccharides | 0.12M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| F2 | 2-14 | Monosaccharides | 0.12M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| F3 | 2-15 | Monosaccharides | 0.12M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| F4 | 2-16 | Monosaccharides | 0.12M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| F5 | 2-17 | Monosaccharides | 0.12M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| F6 | 2-18 | Monosaccharides | 0.12M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| F7 | 2-19 | Monosaccharides | 0.12M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| F8 | 2-20 | Monosaccharides | 0.12M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| F9 | 2-21 | Monosaccharides | 0.12M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| F10 | 2-22 | Monosaccharides | 0.12M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| F11 | 2-23 | Monosaccharides | 0.12M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| F12 | 2-24 | Monosaccharides | 0.12M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |
| G1 | 2-25 | Carboxylic acids | 0.10M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| G2 | 2-26 | Carboxylic acids | 0.10M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| G3 | 2-27 | Carboxylic acids | 0.10M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| G4 | 2-28 | Carboxylic acids | 0.10M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| G5 | 2-29 | Carboxylic acids | 0.10M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| G6 | 2-30 | Carboxylic acids | 0.10M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| G7 | 2-31 | Carboxylic acids | 0.10M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| G8 | 2-32 | Carboxylic acids | 0.10M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| G9 | 2-33 | Carboxylic acids | 0.10M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| G10 | 2-34 | Carboxylic acids | 0.10M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| G11 | 2-35 | Carboxylic acids | 0.10M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| G12 | 2-36 | Carboxylic acids | 0.10M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |
| H1 | 2-37 | Amino acids | 0.10M | 1 | 0.1M | 6.5 | P550MME_P20K | 30.0\% |
| H2 | 2-38 | Amino acids | 0.10M | 1 | 0.1M | 6.5 | EDO_P8K | 30.0\% |
| H3 | 2-39 | Amino acids | 0.10M | 1 | 0.1M | 6.5 | GOL_P4K | 30.0\% |
| H4 | 2-40 | Amino acids | 0.10M | 1 | 0.1M | 6.5 | MPD_P1K_P3350 | 37.5\% |
| H5 | 2-41 | Amino acids | 0.10M | 2 | 0.1M | 7.5 | P550MME_P20K | 30.0\% |
| H6 | 2-42 | Amino acids | 0.10M | 2 | 0.1M | 7.5 | EDO_P8K | 30.0\% |
| H7 | 2-43 | Amino acids | 0.10M | 2 | 0.1M | 7.5 | GOL_P4K | 30.0\% |
| H8 | 2-44 | Amino acids | 0.10M | 2 | 0.1M | 7.5 | MPD_P1K_P3350 | 37.5\% |
| H9 | 2-45 | Amino acids | 0.10M | 3 | 0.1M | 8.5 | P550MME_P20K | 30.0\% |
| H10 | 2-46 | Amino acids | 0.10M | 3 | 0.1M | 8.5 | EDO_P8K | 30.0\% |
| H11 | 2-47 | Amino acids | 0.10M | 3 | 0.1M | 8.5 | GOL_P4K | 30.0\% |
| H12 | 2-48 | Amino acids | 0.10M | 3 | 0.1M | 8.5 | MPD_P1K_P3350 | 37.5\% |

